Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(216)
Activities
(38)
Press/Media
(7)
Prizes
(4)
Datasets
(1)
Supervised work
(12)
ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Astrid Klooster, Marc A. J. Seelen, Arjan Diepstra, Jan-Stephan F. Sanders
A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis
Published in: Haematologica
Access to document
10.3324/haematol.2012.079806
document
Mutations of nucleophosmin 1 are frequently found in acute myeloid leukemia and lead to aberrant cytoplasmic accumulation of nucleophosmin protein. Immunohistochemical staining is therefore recommended as the technique of choice in front-line screening. In this study, we assessed the sensitivity and specificity of immunohistochemistry on formalin-fixed bone marrow biopsies compared with gold standard molecular analysis to predict nucleophosmin 1 mutation status in 119 patients with acute myeloid leukemia. Discrepant cases were further characterized by gene expression analyses and fluorescence in situ hybridization. A large overlap between both methods...
Carolien M. Woolthuis, Andre B. Mulder, Rikst Nynke Verkaik-Schakel, Stefano Rosati, Arjan Diepstra, Eva van den Berg, Jan Jacob Schuringa, Edo Vellenga, Philip M. Kluin, Gerwin Huls
PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0072930
document
Tumor cells of classical Hodgkin lymphoma (cHL) are characterized by a general loss of B cell phenotype, whereas antigen presenting properties are commonly retained. HLA class I is expressed in most EBV+ cHL cases, with an even enhanced expression in a proportion of the cases. Promyelocytic leukemia protein (PML) and special AT-rich region binding protein 1 (SATB1) are two global chromatin organizing proteins that have been shown to regulate HLA class I expression in Jurkat cells. We analyzed HLA class I, number of PML nuclear bodies (NBs) and...
Yuxuan Liu, Anke van den Berg, Rianne Veenstra, Bea Rutgers, Ilja Nolte, Gustaaf van Imhoff, Lydia Visser, Arjan Diepstra
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
Published in: Blood
Access to document
10.1182/blood-2012-06-439570
In classical Hodgkin lymphoma (CHL), 20%-30% of patients experience relapse or progressive disease after initial treatment. The pathogenesis and biology of treatment failure are still poorly understood, in part because the molecular phenotype of the rare malignant Hodgkin Reed-Sternberg (HRS) cells is difficult to study. Here we examined microdissected HRS cells from 29 CHL patients and 5 CHL-derived cell lines by gene expression profiling. We found significant overlap of HL-specific gene expression in primary HRS cells and HL cell lines, but also differences, including surface receptor signaling pathways....
Christian Steidl, Arjan Diepstra, Tang Lee, Fong Chun Chan, Pedro Farinha, King Tan, Adele Telenius, Lorena Barclay, Sohrab P. Shah, Joseph M. Connors, Anke van den Berg, Randy D. Gascoyne
HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0039986
document
The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch cHL patients using a PCR-based sequence-specific oligonucleotide probe (SSOP) hybridization approach. The allele frequencies were compared to HLA typings of more than 6,000 controls. The age of the cHL patients varied between 13 and 81 years with a median of 35 years. Nodular sclerosis subtype was the most common subtype (87%) and EBV was detected in...
Xin Huang, Kushi Kushekhar, Ilja Nolte, Wierd Kooistra, Lydia Visser, Ilby Bouwman, Niels Kouprie, Rianne Veenstra, Gustaaf van Imhoff, Bianca Olver, Richard S. Houlston, Sibrand Poppema, Arjan Diepstra, Bouke Hepkema, Anke van den Berg